Search clinical trials for: Reboxetine

Total 48 results

Pfizer

Completed

A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.

Fibromyalgia

United States
Pfizer

Withdrawn

Maintenance of Efficacy.

Fibromyalgia
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.

Depressive Disorder, Major

Russian Federation, Estonia
Pfizer

Terminated

Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia

Fibromyalgia

Canada, United States, Belgium, Germany, Sweden, Korea, Republic of, Netherlands, United Kingdom, France, Czechia, South Africa
Pfizer

Terminated

A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.

Pain

United States
Pfizer

Completed

A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia

Pain

United States
Pfizer

Completed

Evaluation of A Novel Methodology in the Assessment of Urethral Function Using [S,S]-Reboxetine in Healthy Volunteers

Healthy

Denmark
Pfizer

Completed

[S,S]-Reboxetine Dose-Range Finding Trial

Pain

United States
Axsome Therapeutics, Inc.

Enrolling by invitation

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy

Narcolepsy | Cataplexy | Excessive Daytime Sleepiness

United States, Canada
Pfizer

Terminated

[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.

Pain

Canada, United States, Finland, United Kingdom, Poland, Russian Federation, Argentina, Estonia, Germany, Sweden, India, South Africa, Ukraine, Croatia
Abarbanel Mental Health Center

Unknown

Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia

Schizophrenia

Israel
Axsome Therapeutics, Inc.

Recruiting

A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy (SYMPHONY)

Narcolepsy | Cataplexy | Excessive Daytime Sleepiness

United States, Canada
Pfizer

Terminated

Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

Fibromyalgia

Canada, United States
Pfizer

Completed

A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.

Fibromyalgia

Canada, United States
Axsome Therapeutics, Inc.

Completed

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) (CONCERT)

Narcolepsy | Excessive Sleepiness | Cataplexy Narcolepsy

United States
Pfizer

Terminated

A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

Diabetic Neuropathies

Netherlands, United States, Spain, Finland, South Africa, Czechia
Pfizer

Terminated

[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.

Pain

Canada, United States, India, Chile, Mexico, Spain, United Kingdom, Croatia, Argentina, Lithuania, Poland, Sweden
Pfizer

Completed

Study of [S,S]-Reboxetine in Patients With Postherpetic Neuralgia, Who Are Gabapentin Treatment Failures

Pain
Pfizer

Completed

Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine (ADME)

Healthy

United States
Pfizer

Withdrawn

Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Attention Deficit Hyperactivity Disorder
Hadassah Medical Organization

Completed

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

Major Depressive Disorder

Israel
University Hospital, Basel, Switzerland

Completed

Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)

Substance-related Disorders | Mood Disorder | Amphetamine-related Disorders

Switzerland
Flinders University
Flinders Medical Centre

Not yet recruiting

Reboxetine for Sleep Apnoea After ENT Surgery (RENTOSA)

Sleep Apnea, Obstructive
University Hospital Bispebjerg and Frederiksberg

Completed

Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects

Stress Urinary Incontinence | Fecal Incontinence

Denmark
Hospital Universitari Vall d'Hebron Research Institute

Unknown

Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder

Pain | Abdominal Pain | Major Depression

Spain
University of Pittsburgh

Completed

Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study (TMAO)

Cardiovascular Diseases | Kidney Diseases

United States
Vrije Universiteit Brussel
Science and Research Centre Koper

Recruiting

The Role of the Brain in Mental and Physical Fatigue

Fatigue

Belgium
Zentrum für Integrative Psychiatrie
German Research Foundation

Completed

Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment (Decoflex)

Cognitive Performance in Major Depression

Germany
University of Haifa

Recruiting

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

Posttraumatic Stress Disorder

Israel
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Hypercholesterolaemia

Belgium, Spain, Germany, Austria, Italy, United States, France, Netherlands, Switzerland, United Kingdom
Universitätsklinikum Hamburg-Eppendorf
German Research Foundation; University Hospital Tuebingen

Completed

Enhancement of Motor Function With Reboxetine and Transcranial Direct Current Stimulation (STIMBOX)

Cerebral Stroke

Germany
Dr Cipto Mangunkusumo General Hospital
Indonesia University

Completed

Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients

Graves Disease
Pfizer

Terminated

[S,S]-Reboxetine Add-On Trial

Pain

Canada, Spain, Netherlands, Sweden, Germany, United States, Switzerland, Norway, United Kingdom, Latvia, Russian Federation, Ukraine, Italy, Poland, Czechia, Austria
Guiyang Medical University

Completed

Antidepressants and Bone Mineral Density

Bone Mineral Density Quantitative Trait Locus 7
Geha Mental Health Center

Unknown

Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

Depression

Israel
KBP Biosciences
Medpace, Inc.

Completed

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

Bioequivalence

United States
Antonia New
National Institute of Mental Health (NIMH); New York State Psychiatric Institute

Completed

A D1 Agonist For Working Memory

Schizotypal Personality Disorder | SPD

United States
Teva Pharmaceuticals USA

Completed

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions

Healthy

Canada
Pfizer

Completed

Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers (TQT)

Fibromyalgia

Belgium
Fundació Sant Joan de Déu
Centro de Investigación Biomédica en Red de Salud Mental

Unknown

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Schizophrenia

Spain
University of Oxford

Completed

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

Healthy

United Kingdom
University of Zurich

Completed

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

Healthy

Switzerland
University of Zurich

Recruiting

Studying the Role of Brain Molecules for Decision Making

Healthy | Decision Making

Switzerland
Mental Health Services in the Capital Region, Denmark
University of Copenhagen

Completed

Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder

Major Depressive Disorder

Denmark
National Cancer Institute (NCI)

Active, not recruiting

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
Sultan Qaboos University

Not yet recruiting

Efficacy of Hydroxyzine for Patients With Panic Disorder

Panic Disorder
Hospital Universitari de Bellvitge

Terminated

Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression

Depression

Spain
Hannover Medical School

Terminated

Pharmacovigilance in Gerontopsychiatric Patients (GAP)

Depression | Schizophrenia | Anxiety Disorders | Dementia | Psychosomatic Disorders

Germany

Search clinical trials for: Reboxetine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations